PSNL NASDAQ
Personalis, Inc.
1W: +22.9%
1M: +30.7%
3M: -0.4%
YTD: +5.1%
1Y: +66.3%
3Y: +300.5%
5Y: -58.2%
$8.47
+0.22 (+2.67%)
Weekly Expected Move ±12.3%
$5
$6
$6
$7
$8
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (31)
US Agency Broadens Coverage Of Personalis Breast Cancer Test
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Personalis outlines 2026 clinical volume target of 43,000 to 45,000 tests while reaffirming $78M to $80M revenue guidance
Personalis (PSNL) Q1 2026 Earnings Transcript
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates
Personalis, Inc. $PSNL Shares Acquired by Aberdeen Group plc
Personalis, Inc. (NASDAQ:PSNL) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Personalis (NASDAQ:PSNL) Stock Price Down 9.3% – What’s Next?
Cathie Wood's weekly recap: adds JOBY, CRSP, TEM, sells TER, TXG, CRCL
Personalis (NASDAQ:PSNL) Trading 6.6% Higher – Here’s What Happened
Personalis, Inc. (NASDAQ:PSNL) Sees Large Increase in Short Interest
Personalis, Inc. $PSNL Stake Boosted by ARK Investment Management LLC
Lightspeed Makes a Big Bet on Self-Driving Trucks, Loading Up on 7 Million Shares of Kodiak AI (KDK)
Personalis outlines 170% clinical test volume growth target for 2026 as reimbursement and MRD strategy accelerate
Personalis, Inc. (PSNL) Q4 2025 Earnings Call Transcript
Personalis GAAP EPS of -$0.26 beats by $0.03, revenue of $17.35M beats by $0.23M
Personalis (PSNL) Reports Q4 Loss, Misses Revenue Estimates
Personalis (NASDAQ:PSNL) Shares Down 4.8% – Time to Sell?
Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference
Personalis Gets Medicare Coverage For Lung Cancer Surveillance Test
Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance
Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors
Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Personalis, Inc. (NASDAQ:PSNL) Given Average Rating of “Moderate Buy” by Analysts
Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™
Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights
Personalis, Inc. (NASDAQ:PSNL) Given Average Recommendation of “Moderate Buy” by Brokerages
Personalis, Inc. (NASDAQ:PSNL) Given Consensus Rating of “Moderate Buy” by Brokerages
Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors
New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer
Connor Clark & Lunn Investment Management Ltd. Purchases Shares of 68,679 Personalis, Inc. $PSNL